Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...
Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...
On remand from the Federal Circuit, the Patent Trial and Appeal Board on Thursday reaffirmed its decision that The Broad ...
Morning Overview on MSN
RNA-guided CRISPR tool turns genes on with dose control
Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...
The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...
Scientists at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, have found that gene editing using CRISPR-Cas9 in combination with AAV6 vectors can trigger inflammatory and ...
A new technique may reprogram immune cells inside the body, offering faster, simpler, and more accessible cancer treatment.
A vanadium MXene nanoparticle uses gene editing to strip tumors of heat resistance, then kills them with laser-triggered free ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...
Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results